title: What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Udy
authors.forename: Jason A
authors.initials: JA
authors.lastname: Roberts
authors.forename: Jan J
authors.initials: JJ
authors.lastname: De Waele
authors.forename: David L
authors.initials: DL
authors.lastname: Paterson
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Lipman
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015780:Carbapenems / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D016638:Critical Illness / Q000628:therapy*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D000077726:Doripenem; D006801:Humans; D007668:Kidney / Q000502:physiology*; D008657:Metabolic Clearance Rate; D011014:Pneumonia / Q000188:drug therapy / Q000382:microbiology; D053717:Pneumonia, Ventilator-Associated / Q000188:drug therapy / Q000401:mortality; D016032:Randomized Controlled Trials as Topic
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D002511:Cephalosporins; C443755:ceftobiprole; D000077726:Doripenem